Alar Pharmaceuticals
6785.TWO
4.61 USD
-0.14
-2.95%
a
Overview
Last close
4.61 usd
Market cap
307.98M usd
52 week high
14.52 usd
52 week low
3.82 usd
Target price
8.85 usd
Valuation
P/E
21.4184
Forward P/E
N/A
Price/Sales
21.2672
Price/Book Value
4.0887
Enterprise Value
233.84M usd
EV/Revenue
16.1565
EV/EBITDA
18.0261
Key financials
Revenue TTM
14.47M usd
Gross Profit TTM
14.41M usd
EBITDA TTM
11.85M usd
Earnings per Share
0.22 usd
Dividend
0.05 usd
Total assets
78.46M usd
Net debt
-20.81M usd
About
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.
- Symbol6785.TWO
- ExchangeTWO
- IsinN/A
- CountryTaiwan
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CEODr. Yung-Shun Wen Ph.D.
- HeadquarterTaichung
- Web sitehttps://www.alarpharm.com
